01—Abstract
Summary
Summary of the 10-K filed March 10, 2003. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc.'s 2002 10-K filing highlights a year of significant growth and strategic expansion, largely driven by the transformative acquisition of Immunex Corporation in July 2002.
This acquisition significantly bolstered Amgen's product portfolio and pipeline, particularly in the immunology and inflammation areas, with the addition of ENBREL®. Total revenues increased by 42% to $5.52 billiona, fueled by strong performance from key products like Neulasta™, Aranesp®, and EPOGEN®, alongside the initial contribution from ENBREL®.
Despite a substantial net loss of $1.39 billionb, primarily due to a non-cash write-off of $2.99 billion for acquired in-process research and development related to the Immunex deal, the company's operational performance, excluding this one-time charge, demonstrated robust growth. Amgen maintained a strong financial position with substantial cash reserves, supporting ongoing investments in research and development and strategic initiatives.
02—Key points
Key Highlights
- Total revenues surged 42% to $5.52 billion, driven by strong product sales and the significant Immunex acquisition.
- The acquisition of Immunex Corporation in July 2002 for approximately $17.8 billion significantly expanded Amgen's product portfolio and R&D capabilities.
- Net loss of $1.39 billion reported, largely due to a $2.99 billion write-off of acquired in-process R&D from the Immunex acquisition.
- Key product sales growth was notable for Neulasta™ (launched April 2002), Aranesp®, and EPOGEN®, indicating strong market demand.
- ENBREL®, acquired through Immunex, contributed $362.1 million in sales in the latter half of 2002, despite supply constraints.
- Operating expenses increased significantly, driven by R&D and SG&A investments, including integration costs related to Immunex.
- Amgen maintained a strong liquidity position, ending the year with $4.66 billion in cash, cash equivalents, and marketable securities.
03—Questions
Frequently Asked Questions
What was the primary driver of Amgen's significant revenue growth in 2002?
The primary driver of Amgen's significant revenue growth in 2002 was the acquisition of Immunex Corporation in July 2002, which added ENBREL® to its product portfolio and contributed substantially to the company's overall sales. Strong performance from existing products like Neulasta™, Aranesp®, and EPOGEN® also contributed significantly.
Why did Amgen report a net loss in 2002 despite strong revenue growth?
Amgen reported a net loss of $1.39 billion primarily due to a significant one-time, non-cash charge of $2.99 billion for acquired in-process research and development related to the Immunex acquisition. This charge is an accounting treatment for the estimated fair value of purchased R&D projects that had not yet reached technological feasibility.
How did the Immunex acquisition impact Amgen's business and financial statements?
The Immunex acquisition was transformative, adding ENBREL® (a key product in the inflammation and immunology space) and strengthening Amgen's pipeline and R&D capabilities. Financially, it led to a significant increase in total assets, revenues, and operating expenses. The acquisition's accounting also resulted in a large IPR&D charge, impacting net income, and the creation of substantial goodwill on the balance sheet.
What are Amgen's key products and their performance in 2002?
Amgen's key products in 2002 included EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta™ (pegfilgrastim), and ENBREL® (etanercept). EPOGEN® sales grew 7%, NEUPOGEN® sales grew 2% (while Neulasta™ began converting NEUPOGEN® patients), Aranesp® sales increased significantly with new indications, Neulasta™ generated $463.5 million in its first year, and ENBREL® contributed $362.1 million in sales from mid-July 2002.
04—Continue